The SURMOUNT phase 3 trials evaluated tirzepatide versus placebo in people with obesity or overweight with at least 1 ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Eli Lilly announced the latest results from the SURMOUNT-1 three-year study on the efficacy of tirzepatide in an Aug. 20 ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

When Lilly reported strong results from SURMOUNT-1 earlier this year, the drugmaker suggested it may be able to file for approval of tirzepatide in obesity before the end of this year. That won't ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

SURMOUNT-1 (Tirzepatide): Patients lost up to 52 lbs (22.5 kg) in the highest dosage group. User Reports: Many patients experience consistent weight loss, enhanced metabolic health, and improved ...

Obesity is a common health problem affecting a considerable (and growing) proportion of adult populations worldwide.1 Although overweight and obesity are usually diagnosed by anthropometry, such as ...

While studies show that tirzepatide is safe overall, the long-term effects are still unknown and need to be further evaluated. In the SURMOUNT-4 clinical trial, researchers found that stopping ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...

SURMOUNT-1 (Tirzepatide): Patients lost up to 52 lbs (22.5 kg) in the highest dosage group. Real-World Patient Data: Many users report consistent weight loss, improved metabolic health ...